Gene therapy company needs to raise additional €10 million to sustain activities to next milestone. GenSight Biologics, a biopharma specializing in gene therapies for retinal neurodegenerative diseases, has announced the successful confirmation of the second Good Manufacturing Practice (GMP) batch of its lead product candidate LUMEVOQ. This event means the French biotech is now eligible to draw down the €4 million second tranche of a bridge financing agreed with Sofinnova Partners, Invus and UPMC Enterprises. GenSight is developing a pipeline of therapies using mitochondrial targeting sequence and optogenetics technologies to address retinal diseases and central nervous system disorders. The company…
Author: Michael
For people who have gotten a flu shot heading in
Nutrition and diabetes experts offer tips for de
Managing fatigue is a big part of living with my
What are the new treatments for myasthenia gravi
Highly successful cognitive processing therapy h
Myasthenia gravis finances: What to expect, what
Myasthenia gravis issues: health disparities, qu
A person with myasthenia gravis shares how to ma
Managing triggers is key to living well with mya